DOI: http://dx.doi.org/10.18203/2349-2902.isj20205446

Clinical presentation and hormonal profile of patients with pituitary tumour

Shaju Mathew, Geo Paul Jose Kurikkattayil, Kunjan Balakrishnan Paruvakkattil, Ebitha Elias Kalarikkal

Abstract


Background: Pituitary tumours represent about 10% of intracranial tumours. To know about the common clinical presentations and hormone profile of patients with pituitary tumour help in early diagnosis and treatment of the disease.

Methods: A prospective study was carried out for a duration of 16 months from 1st June 2018 to 30th September 2019, among 93 patients admitted with diagnosis of pituitary tumour in department of neurosurgery in a tertiary care centre. Study involved initial clinical assessment followed by assessment of hormone profile. In the end of the study the most common clinical presentation and the common pituitary hormones that were deranged in those cases were found out. Statistical analysis was done to find out relationship between hormone levels and clinical symptoms.

Results: From the study it was found that the most common clinical presentations of pituitary tumour were headache [58 patients (62.4%)] and visual disturbance [53 patients (56.9%)]. Hormone over production was reported in 35 patients (37.6%), of which 25 patients (26.9%) were having high prolactin levels. Most common hormone that showed below normal values in pituitary tumour patients was luteinizing hormone (LH), in 19 patients (19.35%). Study also found out statistically significant association between elevated prolactin levels and headache.

Conclusions: In patients with pituitary tumours most common clinical presentations included headache and visual disturbance. Prolactin was the most common hormone which was above normal levels. Most common hormone that was below normal levels were gonadotropins.


Keywords


Pituitary, Prolactin, LH

Full Text:

PDF

References


Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011;96(6):1633-41.

Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J et al. Tumours of the pituitary gland. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C., eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Endocrine Organs. Vol. 8. 3rd ed. Lyon, France: IARC Press. 2004;9-47.

Jane JA Jr, Laws ER Jr. The surgical management of pituitary adenomas in a series of 3,093 patients. J Am Coll Surg. 2001;193(6):651-9.

Thapar K, Kovacs K, Muller PJ. Clinical-pathological correlations of pituitary tumours. Baillieres Clin Endocrinol Metab. 1995;9(2):243-70.

Gittleman H, Ostrom QT, Farah PD, Ondracek A, Chen Y, Wolinsky Y et al. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. J Neurosurg. 2014;121:527-35.

Bhuyan M, Sarma D, Dutta D, Yadav Y, Das S. Clinicopathological study of pituitary adenomas in the region of northeast India. J Arab Society Med Res. 2016;11:43-9.

Wilson CB. Neurosurgical management of large and invasive pituitary tumors. In: Tindall GT, Collins WF, eds. Clinical Management of Pituitary Disorders. New York: Raven Press. 1979:335-42.

Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg. 1984;61(5):814-33.

Wakai S, Fukushima T, Teramoto A, Sano K. Pituitary Apoplexy: Its Incidence and Clinical Significance. J Neurosurg. 19 81;55:187-93.

Molitch ME. Incidental pituitary adenomas. Am J Med Sci. 1993;306(4):262-4.

Biller BM, Swearingen B, Zervas NT. A decade of the Massachusetts General Hospital Neuroendocrine Clinical Center. J Clin Endocrin ol Metab. 1997;82:1668-74.